Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Sep 20;20(9):645-651.
doi: 10.3779/j.issn.1009-3419.2017.09.10.

[Novel Immuno-oncology Therapy: Current Status of Clinical Research and Prospect of Application]

[Article in Chinese]
Shijia Zhang  1 , Shengxiang Ren  1
Affiliations
Review

[Novel Immuno-oncology Therapy: Current Status of Clinical Research and Prospect of Application]

[Article in Chinese]
Shijia Zhang et al. Zhongguo Fei Ai Za Zhi. .

Abstract
in English, Chinese

Recently, immune-oncologic therapy advanced rapidly and has been defined as another option, following surgery, radiotherapy, chemotherapy and molecular targeted therapy, for treatment of malignant diseases. To date, several immune checkpoint inhibitors and compounds have been approved to treat various of malignant diseases with efficiency. Meanwhile, more and more potential therapeutic targets in processes of the cancer immunity have been noticed. We aimed to summarize the research status and clinical prospects of novel immune-oncologic treatment agencies targeted to different steps of the cancer-immunity cycle.

近年来，免疫肿瘤治疗发展迅速，已经成为继手术、放疗、化疗、靶向治疗后癌症的另一有效治疗手段。目前已有多个免疫检查点相关药物获批用于多种恶性肿瘤的治疗，而且越来越多的潜在治疗靶点受到关注。本综述旨在根据肿瘤-免疫循环中的不同环节，对不同机制的免疫肿瘤治疗药物研究现状和临床前景进行概述和展望。.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Hoos A. Development of immuno-oncology drugs -from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov. 2016;15(4):235–247. doi: 10.1038/nrd.2015.35. - DOI - PubMed

    1. U. S. Food and Drug Administration. Hematology/Oncology (Cancer) Approvals & Safety Notifications. <a href="http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm" target="_blank">http://www.fda.gov/Drugs/InformationOnDrugs/Approved Drugs/ucm279174.htm</a>

    1. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10. doi: 10.1016/j.immuni.2013.07.012. - DOI - PubMed
    1. Galluzzi L, Vacchelli E, Bravo-San P J, et al. Classification of current anticancer immunotherapies. https://www.researchgate.net/publication/270004313_Classification_of_cur.... Oncotarget. 2014;5(24):12472–12508. - PMC - PubMed
    1. Brahmer J, Horn L, Jackman D, et al. Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC): Clinical characteristics of long-term survivors. http://cancerres.aacrjournals.org/content/77/13_Supplement/CT077 Cancer Res. 2017;77(13 Suppl):Abstract CT077.